CLAIMS:

1. An oncogenic protein kinase.

CLAIMS

1. A salt selected from the group consisting of:

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt, wherein the salt is crystalline;

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt, wherein the salt is crystalline; and

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt, wherein the salt is crystalline.

2. The crystalline salt of claim 1, which is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

3. The crystalline salt of claim 1, which is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt.

4. The crystalline salt of claim 1, which is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt.

5. The crystalline salt of claim 2, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid.

6. The crystalline salt of claim 3, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:sulfuric acid.

7. The crystalline salt of claim 4, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:maleic acid.

8. A pharmaceutical formulation comprising the crystalline salt of any one of claims 1 to 7 and a pharmaceutically acceptable carrier.

9. A dosage form comprising a salt selected from the group consisting of

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt,

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt, and

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt.

10. A dosage form comprising the pharmaceutical formulation of claim 8

11. The dosage form of claim 9 or claim 10, wherein the dosage form is suitable for oral administration.

12. The dosage form of claim 11, wherein the dosage form is a tablet.

13. Use of a salt of selected from:

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt, wherein the salt is crystalline;

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt, wherein the salt is crystalline; and

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt

in the preparation of a medicament for treating a disease in a patient, wherein said disease is associated with JAK activity, and wherein said disease is: a viral disease, ischemia reperfusion, anorexia resulting from or associated with cancer, cachexia resulting from or associated with cancer, or fatigue resulting from or associated with cancer.

14. The use of claim 13, wherein the salt is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

15. The use of claim 13 or 14, wherein said disease is a viral disease.

16. The use of claim 15, wherein said viral disease is Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV), or Human Papilloma Virus (HPV).

17. The use of claim 13 or 14, wherein said disease is ischemia reperfusion or related to an ischemic event.

18. The use of claim 13 or 14, wherein said disease is anorexia or cachexia resulting from or associated with cancer.

19. The use of claim 13 or 14, wherein said disease is fatigue resulting from or associated with cancer.